{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:14:41Z","timestamp":1791918881704,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Mantle cell lymphoma (MCL) is a well-defined aggressive lymphoid neoplasm characterized by proliferation of mature B-lymphocytes that have a remarkable tendency to disseminate. This tumor is considered as one of the most aggressive lymphoid neoplasms with poor responses to conventional chemotherapy and relatively short survival. Since cyclin D1 and cell cycle control appears as a natural target, small-molecule inhibitors of cyclin-dependent kinases (Cdks) and cyclins may play important role in the therapy of this disorder. We explored P276-00, a novel selective potent Cdk4-D1, Cdk1-B and Cdk9-T1 inhibitor discovered by us against MCL and elucidated its potential mechanism of action.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The cytotoxic effect of P276-00 in three human MCL cell lines was evaluated <jats:italic>in vitro<\/jats:italic>. The effect of P276-00 on the regulation of cell cycle, apoptosis and transcription was assessed, which are implied in the pathogenesis of MCL. Flow cytometry, western blot, immunoflourescence and siRNA studies were performed. The <jats:italic>in vivo<\/jats:italic> efficacy and effect on survival of P276-00 was evaluated in a Jeko-1 xenograft model developed in SCID mice. PK\/PD analysis of tumors were performed using LC-MS and western blot analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>P276-00 showed a potent cytotoxic effect against MCL cell lines. Mechanistic studies confirmed down regulation of cell cycle regulatory proteins with apoptosis. P276-00 causes time and dose dependent increase in the sub G1 population as early as from 24 h. Reverse transcription PCR studies provide evidence that P276-00 treatment down regulated transcription of antiapoptotic protein Mcl-1 which is a potential pathogenic protein for MCL. Most importantly, <jats:italic>in vivo<\/jats:italic> studies have revealed significant efficacy as a single agent with increased survival period compared to vehicle treated. Further, preliminary combination studies of P276-00 with doxorubicin and bortezomib showed <jats:italic>in vitro<\/jats:italic> synergism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our studies thus provide evidence and rational that P276-00 alone or in combination is a potential therapeutic molecule to improve patients\u2019 outcome in mantle cell lymphoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1476-4598-11-77","type":"journal-article","created":{"date-parts":[[2012,10,18]],"date-time":"2012-10-18T19:16:12Z","timestamp":1350587772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines"],"prefix":"10.1186","volume":"11","author":[{"given":"Nitesh P","family":"Shirsath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal M","family":"Manohar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana S","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,18]]},"reference":[{"key":"1074_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","volume":"142","author":"P Jares","year":"2008","unstructured":"Jares P, Campo E: Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008, 142: 149-165. 10.1111\/j.1365-2141.2008.07124.x","journal-title":"Br J Haematol"},{"key":"1074_CR2","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-09-2484","volume":"16","author":"Q Liu","year":"2010","unstructured":"Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N: FTY720 shows promising in vitro and in vivo preclinical activity by down modulating cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res. 2010, 16: 3182-3192. 10.1158\/1078-0432.CCR-09-2484","journal-title":"Clin Cancer Res"},{"key":"1074_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","volume":"114","author":"M Ghielmini","year":"2009","unstructured":"Ghielmini M, Zucca E: How I treat mantle cell lymphoma. Blood. 2009, 114: 1469-1476. 10.1182\/blood-2009-02-179739","journal-title":"Blood"},{"key":"1074_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/oxfordjournals.annonc.a059154","volume":"6","author":"AJ Norton","year":"1995","unstructured":"Norton AJ, Matthews J, Pappa V, Shamash J, Love S, Rohatiner AZ, Lister TA: Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol. 1995, 6: 249-256.","journal-title":"Ann Oncol"},{"key":"1074_CR5","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/sj.cdd.4400758","volume":"7","author":"M Jourdan","year":"2000","unstructured":"Jourdan M, De Vos J, Mechti N, Klein B: Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-a and insulin-like growth factor 1. Cell Death Differ. 2000, 7: 1244-1252. 10.1038\/sj.cdd.4400758","journal-title":"Cell Death Differ"},{"key":"1074_CR6","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.leukres.2006.03.004","volume":"30","author":"G Venkataraman","year":"2006","unstructured":"Venkataraman G, Maududi T, Ozpuyan F, Bahar HI, Izban KF, Qin JZ, Alkan S: Induction of apoptosis and down regulation of cell cycle protein in mantle cell lymphoma by flavopiridol treatment. Leuk Res. 2006, 30: 1377-1384. 10.1016\/j.leukres.2006.03.004","journal-title":"Leuk Res"},{"key":"1074_CR7","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2009.019745","volume":"95","author":"F Baran-Marszak","year":"2010","unstructured":"Baran-Marszak F, Boukhiar M, Harel S, Laquillier C, Roger C, Gressin R, Martin A, Fagard R, Varin-Blank N, Ajchenbaum-Cymbalista F, Ledoux D: Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. 2010, 95: 1865-1872. 10.3324\/haematol.2009.019745","journal-title":"Haematologica"},{"key":"1074_CR8","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.3816\/CLM.2007.s.021","volume":"7","author":"A Goy","year":"2007","unstructured":"Goy A, Feldman T: Expanding therapeutic options in mantle cell lymphoma. Clin Lymphoma Myeloma. 2007, 7: S184-S191.","journal-title":"Clin Lymphoma Myeloma"},{"key":"1074_CR9","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1158\/0008-5472.CAN-09-3578","volume":"70","author":"R Chen","year":"2010","unstructured":"Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W: Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 2010, 70: 6587-6597. 10.1158\/0008-5472.CAN-09-3578","journal-title":"Cancer Res"},{"key":"1074_CR10","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3324\/haematol.2009.013359","volume":"94","author":"SA Pileri","year":"2009","unstructured":"Pileri SA, Falini B: Mantle cell lymphoma. Haematologica. 2009, 94: 1488-1492. 10.3324\/haematol.2009.013359","journal-title":"Haematologica"},{"key":"1074_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood.V99.1.238","volume":"99","author":"E Camacho","year":"2002","unstructured":"Camacho E, Hernandez L, Hernandez S, Tort F, Bellosillo B, Bea S, Bosh F, Montserrat E, Cardesa A, Fern\u00e1ndez PL, Campo E: ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood. 2002, 99: 238-244. 10.1182\/blood.V99.1.238","journal-title":"Blood"},{"key":"1074_CR12","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1182\/blood.V99.8.3075","volume":"99","author":"A Hangaishi","year":"2002","unstructured":"Hangaishi A, Ogawa S, Qiao Y, Wang L, Hosoya N, Yuji K, Imai Y, Takeuchi K, Miyawaki S, Hirai H: Mutations of Chk2 in primary hematopoietic neoplasms. Blood. 2002, 99: 3075-3077. 10.1182\/blood.V99.8.3075","journal-title":"Blood"},{"key":"1074_CR13","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1182\/blood-2002-04-1078","volume":"100","author":"F Tort","year":"2002","unstructured":"Tort F, Hernandez S, Bea S, Martinez A, Esteller M, Herman JG, Puig X, Camacho E, Sanchez M, Nayach I, Lopez-Guillermo A, Fernandez PL, Colomer D, Hernandez L, Campo E: CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood. 2002, 100: 4602-4608. 10.1182\/blood-2002-04-1078","journal-title":"Blood"},{"key":"1074_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/A:1008207005567","volume":"8","author":"CI de Boer","year":"1997","unstructured":"de Boer CI, Krieken J, Schuuring E, Kluin PM: Bcl-1\/cyclin D1 in malignant lymphoma. Ann Oncol. 1997, 8: 109-117.","journal-title":"Ann Oncol"},{"key":"1074_CR15","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood.V88.1.268.268","volume":"88","author":"LR Zukerberg","year":"1996","unstructured":"Zukerberg LR, Benedict WF, Arnold A, Dyson N, Harlow E, Harris NL: Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. Blood. 1996, 88: 268-276.","journal-title":"Blood"},{"key":"1074_CR16","first-page":"1591","volume":"148","author":"P Jares","year":"1996","unstructured":"Jares P, Campo E, Pinyol M, Bosch F, Miquel R, Fernandez PL, Sanchez-Beato M, Soler F, Perez-Losada A, Nayach I, Mallofre C, Piris MA, Montserrat E, Cardesa A: Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1\/CCND1) mRNA levels and proliferative activity. Am J Pathol. 1996, 148: 1591-1600.","journal-title":"Am J Pathol"},{"key":"1074_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","volume":"16","author":"L Paoluzzi","year":"2010","unstructured":"Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O\u2019Connor OA: Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res. 2010, 16: 554-565. 10.1158\/1078-0432.CCR-09-1937","journal-title":"Clin Cancer Res"},{"key":"1074_CR18","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.biocel.2007.04.026","volume":"39","author":"F Bertoni","year":"2007","unstructured":"Bertoni F, Ponzoni M: The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol. 2007, 39: 1747-1753. 10.1016\/j.biocel.2007.04.026","journal-title":"Int J Biochem Cell Biol"},{"key":"1074_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/path.1254","volume":"199","author":"JD Khoury","year":"2003","unstructured":"Khoury JD, Medeiros LJ, Rassidakis GZ, McDonnell TJ, Abruzzo LV, Lai R: Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol. 2003, 199: 90-97. 10.1002\/path.1254","journal-title":"J Pathol"},{"key":"1074_CR20","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1158\/1535-7163.MCT-06-0613","volume":"6","author":"KS Joshi","year":"2007","unstructured":"Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S: In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007, 6: 918-925. 10.1158\/1535-7163.MCT-06-0613","journal-title":"Mol Cancer Ther"},{"key":"1074_CR21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/1535-7163.MCT-06-0614","volume":"6","author":"KS Joshi","year":"2007","unstructured":"Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, Chile S, Sivakumar S, Maier A, Fiebig HH, Sharma S: P276-00 a novel cyclin-dependent inhibitor induces G1\u2013G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007, 6: 926-934. 10.1158\/1535-7163.MCT-06-0614","journal-title":"Mol Cancer Ther"},{"key":"1074_CR22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.leukres.2010.12.010","volume":"35","author":"SM Manohar","year":"2011","unstructured":"Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS: Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res. 2011, 35: 821-830. 10.1016\/j.leukres.2010.12.010","journal-title":"Leuk Res"},{"key":"1074_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/pcan.2011.51","volume":"15","author":"SM Manohar","year":"2012","unstructured":"Manohar SM, Padgoankar A, Jalota-Badhwar A, Rao SV, Joshi KJ: Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1\u03b1 and induces G2\/M arrest under hypoxia in prostate cancer cells. Prostate Cancer Prostatic Dis. 2012, 15: 15-27. 10.1038\/pcan.2011.51","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1074_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC: Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 2010, 70: 440-446. 10.1158\/0008-5472.CAN-09-1947","journal-title":"Cancer Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-11-77.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:52:08Z","timestamp":1630533128000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-11-77"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,18]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-11-77","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,18]]},"assertion":[{"value":"18 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"77"}}